Atara Biotherapeutics (NASDAQ:ATRA) released its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.40) by $0.09, Fidelity Earnings reports.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of ATRA opened at $13.57 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.56 and a quick ratio of 9.56. The business’s fifty day moving average price is $13.00 and its 200 day moving average price is $16.10. The stock has a market capitalization of $769.48 million, a PE ratio of -2.57 and a beta of 2.04. Atara Biotherapeutics has a 12-month low of $10.38 and a 12-month high of $43.94.
In related news, insider Joe Newell sold 3,500 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $13.51, for a total transaction of $47,285.00. Following the completion of the transaction, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.00% of the company’s stock.
A number of brokerages have recently weighed in on ATRA. Jefferies Financial Group cut Atara Biotherapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $32.00 to $15.00 in a research report on Monday, September 16th. ValuEngine raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Stifel Nicolaus reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, October 25th. Citigroup set a $14.00 price target on Atara Biotherapeutics and gave the stock a “hold” rating in a research note on Monday, August 12th. Finally, Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $28.22.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: How to Invest in a Bull Market